albicans isolates were tested for slime production with modified tube adherence JPH203 clinical trial test and antifungal resistance with disk diffusion method.

Results: Slime positivity was 31.3 % in all Candida species. Slime positivity in non-C. albicans isolates (44.89 %) was higher than in C. albicans species (21.21 %). All C. albicans isolates were sensitive to fluconazole and voriconazole. The highest resistance to fluconazole

(40 %) and voriconazole (5%) was by C. glabrata strains.

Conclusion: Species definition and determination the proper management and treatment of patients.”
“Background: Blood pressure is considered to be a leading example of a valid surrogate endpoint. The aims of this study were to (i) formally evaluate systolic and diastolic blood pressure reduction as a surrogate endpoint for stroke prevention and (ii) determine what blood pressure reduction would predict a stroke benefit.

Methods: We identified randomised trials of at least six months duration comparing any pharmacologic antihypertensive treatment to placebo or no treatment, and reporting baseline blood pressure, on-trial blood pressure,

and fatal and non-fatal stroke. Trials with fewer than PU-H71 five strokes in at least one arm were excluded. Errors-in-variables weighted least squares regression modelled the reduction in stroke as a function of systolic blood pressure reduction and diastolic blood pressure reduction respectively. The lower 95% prediction band was used to determine the minimum systolic blood pressure and diastolic blood pressure difference, the surrogate threshold effect (STE), below which there would be no predicted stroke Dihydrotestosterone nmr benefit. The STE was used to generate the surrogate threshold effect proportion (STEP), a surrogacy metric, which with the R-squared trial-level association was used to evaluate blood pressure as a surrogate endpoint for stroke using the

Biomarker-Surrogacy Evaluation Schema (BSES3).

Results: In 18 qualifying trials representing all pharmacologic drug classes of antihypertensives, assuming a reliability coefficient of 0.9, the surrogate threshold effect for a stroke benefit was 7.1 mmHg for systolic blood pressure and 2.4 mmHg for diastolic blood pressure. The trial-level association was 0.41 and 0.64 and the STEP was 66% and 78% for systolic and diastolic blood pressure respectively. The STE and STEP were more robust to measurement error in the independent variable than R-squared trial-level associations. Using the BSES3, assuming a reliability coefficient of 0.9, systolic blood pressure was a B + grade and diastolic blood pressure was an A grade surrogate endpoint for stroke prevention. In comparison, using the same stroke data sets, no STEs could be estimated for cardiovascular (CV) mortality or all-cause mortality reduction, although the STE for CV mortality approached 25 mmHg for systolic blood pressure.